ADAPTIMMUNE THERAPEUTICS Reports Q4 FY2022 Earnings Results on December 31, 2022

Earnings Overview

ADAPTIMMUNE THERAPEUTICS ($NASDAQ:ADAP) announced their Q4 FY2022 earnings results on December 31 2022, with total revenue increasing 24.7% from the same period of the previous year, to USD -29.2 million. Net income also rose 676.8%, reaching USD 11.0 million.

Transcripts Simplified

The most recent earnings transcripts for Adaptimmune Therapeutics can be found on the company’s Investor Relations website. The transcripts can be found in the Financial Reports section and are usually published on the same day as the earnings calls. They include information such as financial results, operational updates, and any accompanying commentary from company executives. The transcripts also include questions and answers from analysts and investors who participated in the call.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Adaptimmune Therapeutics. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Adaptimmune Therapeutics. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Adaptimmune Therapeutics. More…

Key Ratios Snapshot

Some of the financial key ratios for Adaptimmune Therapeutics are shown below. More…

Stock Price

The stock opened at $1.4 and closed at $1.3, resulting in a 25.0% plunge from its last closing price of 1.8. This drop was unexpected and the market reacted to the news with great surprise. The financial results showed a decrease in revenue as compared to the previous quarter, and a decrease in net income as well. These results led investors to speculate that ADAPTIMMUNE THERAPEUTICS is facing difficulties in driving growth and profitability in the near future.

It remains to be seen how the company will respond to this news and the current market conditions. Investors are waiting for more details on the future of ADAPTIMMUNE THERAPEUTICS and whether it will be able to turn things around. Live Quote…

Analysis

At GoodWhale, we recently conducted an analysis of ADAPTIMMUNE THERAPEUTICS’s wellbeing. We concluded that they are a medium risk investment in terms of financial and business aspects. To arrive at this conclusion, we closely inspected their balance sheet, cashflow statement, and financial journal. In doing so, we uncovered three risk warnings that are worth looking into. If you’re interested in learning more about our findings, please sign up with us and we’d be happy to discuss the potential risks in greater detail. More…

Peers

The company’s T-cell therapy platform harnesses the body’s own immune system to target and kill cancer cells. Adaptimmune’s lead product candidate, ADAPT-101, is in clinical trials for the treatment of solid tumors. The company is also developing product candidates for the treatment of blood cancers. Adaptimmune’s main competitors are Iovance Biotherapeutics Inc, TCR2 Therapeutics Inc, and Adicet Bio Inc. All three companies are developing T-cell therapies for the treatment of cancer.

– Iovance Biotherapeutics Inc ($NASDAQ:IOVA)

Iovance Biotherapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of cancer immunotherapy products. The company has a market cap of 1.24B as of 2022 and a Return on Equity of -56.45%. The company’s products are based on its proprietary technology platform, which harnesses the power of the body’s immune system to recognize and kill cancer cells. Iovance Biotherapeutics Inc’s products are in clinical and commercial development stages for the treatment of various solid tumor types.

– TCR2 Therapeutics Inc ($NASDAQ:TCRR)

The company’s market cap is 49.48 million as of 2022, a return on equity of -24.78%. The company is focused on the development of immunotherapies for the treatment of cancer.

– Adicet Bio Inc ($NASDAQ:ACET)

Adicet Bio Inc is a clinical stage biopharmaceutical company focused on developing next-generation cell therapies for cancer and other intractable diseases. The company’s lead product candidate, ADI-001, is a universal donor platform cell therapy using allogeneic, or donor-derived, gamma delta T cells that can be used to treat any patient, without the need for human leukocyte antigen (HLA) matching. The company is also developing ADI-002, a natural killer cell therapy platform for the treatment of solid tumors.

Adicet Bio Inc has a market cap of 836.46M as of 2022, a Return on Equity of -9.85%. Adicet Bio is a clinical stage biopharmaceutical company focused on developing next-generation cell therapies for cancer and other intractable diseases. The company’s lead product candidate, ADI-001, is a universal donor platform cell therapy using allogeneic, or donor-derived, gamma delta T cells that can be used to treat any patient, without the need for human leukocyte antigen (HLA) matching. The company is also developing ADI-002, a natural killer cell therapy platform for the treatment of solid tumors.

Summary

ADAPTIMMUNE THERAPEUTICS reported their Q4 FY2022 results, with total revenue of USD -29.2 million and a net income of USD 11.0 million, representing a 24.7% increase in revenue and a 676.8% increase in net income from the same period last year. Although the revenue was negative, investors reacted negatively to the news and the stock price declined. This could indicate that investors are foreseeing potential challenges ahead for the company, or that they were expecting more significant improvements in revenue and/or net income. Investors should continue to closely monitor ADAPTIMMUNE’s performance, taking into account its past financial performance, outlook, and current market conditions.